Brief: CHMP Recommends Granting Marketing Authorisation For Rasonque For Metastatic Pancreatic Cancer In EU
15/10/2026 15:35
BRIEF-CHMP Recommends Granting Marketing Authorisation For Rasonque For Metastatic Pancreatic Cancer In EU Oct 15 (Reuters) - EMA:
EMA: CHMP HAS RECOMMENDED GRANTING A MARKETING AUTHORISATION IN EUROPEAN UNION FOR RASONQUE (DARAXONRASIB) FOR METASTATIC PANCREATIC CANCER
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Revolution Medicines
See all newsAnalysis: Revolution Medicines' Europe efforts signal solo launch ambitions for cancer drug
Brief: CHMP Recommends Granting Marketing Authorisation For Rasonque For Metastatic Pancreatic Cancer In EU
Revolution Medicines wins EU committee backing for pancreatic cancer treatment (updated)
EMA recommends approval of Revolution's pancreatic cancer drug
Revolution Medicines falls on pancreatic cancer drug data concerns